TRANSITION SERVICES AGREEMENTTransition Services Agreement • May 3rd, 2004 • Pharmacopeia Inc • Services-prepackaged software • Delaware
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionTHIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is dated as of this 30th day of April, 2004, by and between PHARMACOPEIA, INC., a Delaware corporation (“Pharmacopeia”), and ACCELRYS INC., a Delaware corporation and a wholly owned subsidiary of Pharmacopeia (Pharmacopeia and Accelrys Inc. are referred to herein collectively as “Accelrys”), on the one hand, and PHARMACOPEIA DRUG DISCOVERY, INC., a Delaware corporation (“PDD”), on the other hand. Each of Accelrys and PDD is sometimes hereinafter referred to as a “Party” and together as the “Parties.”
TAX SHARING AND INDEMNIFICATION AGREEMENTTax Sharing and Indemnification Agreement • May 3rd, 2004 • Pharmacopeia Inc • Services-prepackaged software • Delaware
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionThis Tax Sharing and Indemnification Agreement (this “Agreement”) is entered into as of the Distribution Date by and between Pharmacopeia, Inc., a Delaware corporation (“Pharmacopeia”), on behalf of itself and each Pharmacopeia Affiliate, and Pharmacopeia Drug Discovery, Inc., a Delaware corporation (“PDD”), and their respective successors.
EMPLOYEE MATTERS AGREEMENT dated as of April 30, 2004 between PHARMACOPEIA, INC. and PHARMACOPEIA DRUG DISCOVERY, INC.Employee Matters Agreement • May 3rd, 2004 • Pharmacopeia Inc • Services-prepackaged software • Delaware
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionTHIS IS AN EMPLOYEE MATTERS AGREEMENT, dated as of April 30, 2004 (the “Agreement”), by and between Pharmacopeia, Inc., a Delaware corporation (together with its successors and permitted assigns, “Supplier”), and Pharmacopeia Drug Discovery, Inc., a Delaware corporation (together with its successors and permitted assigns, “Spinco”) (collectively, the “Parties” or individually, a “Party”).
PATENT AND SOFTWARE LICENSE AGREEMENTPatent and Software License Agreement • May 3rd, 2004 • Pharmacopeia Inc • Services-prepackaged software • Delaware
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionThis PATENT AND SOFTWARE LICENSE AGREEMENT (the “Agreement”), effective this 30th day of April, 2004 (the “Effective Date”), is between Pharmacopeia Drug Discovery, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 3000 Eastpark Boulevard, Cranbury New Jersey 08512 (“PDD”), and Pharmacopeia, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 9685 Scranton Road, San Diego, California 92121-3752 (“Pharmacopeia”), for itself and on behalf of Accelrys Inc. and each of Pharmacopeia’s subsidiaries other than PDD (Pharmacopeia and such subsidiaries other than PDD being referred to herein collectively as the “Pharmacopeia Group”).
MASTER SEPARATION AND DISTRIBUTION AGREEMENT BETWEEN PHARMACOPEIA, INC., ACCELRYS INC. AND PHARMACOPEIA DRUG DISCOVERY, INC.Master Separation and Distribution Agreement • May 3rd, 2004 • Pharmacopeia Inc • Services-prepackaged software • Delaware
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionTHIS MASTER SEPARATION AND DISTRIBUTION AGREEMENT (this “Agreement”) is entered into as of April 30, 2004, between Pharmacopeia, Inc., a Delaware corporation (“Pharmacopeia”), Accelrys Inc., a Delaware corporation (“Accelrys”), and Pharmacopeia Drug Discovery, Inc., a Delaware corporation (“PDD”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in Article VI hereof.
DISENGAGEMENT AGREEMENT AND RELEASEDisengagement Agreement • May 3rd, 2004 • Pharmacopeia Inc • Services-prepackaged software • New Jersey
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionThis Disengagement Agreement and Release (the “Agreement”) is entered into as of the 31st day of March, 2004, by and between PHARMACOPEIA, INC., a Delaware corporation (the “Company”), and JOSEPH A. MOLLICA, (hereinafter, “Dr. Mollica”).